- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05153811
The Less is More Study
July 29, 2025 updated by: University of Florida
Novel Extensions of Alcohol Contingency Management in People Living With HIV
In this project, the investigators will implement innovations to extend use of Contingency Management (CM) to facilitate alcohol use reduction among people living with HIV (PLWH).
The investigators' approach to extending CM will use mobile health (mHealth) tools including a smartphone breathalyzer device with accompanying app and a wrist worn alcohol biosensor.
Participants will be engaged in mobile facilitated CM for 30-60 days with follow-up out to 6 months.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emmely Pavila
- Phone Number: 352-273-9562
- Email: empavila17@ufl.edu
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Recruiting
- University of Miami
-
Contact:
- Varan Govind, PhD
- Phone Number: 305-243-8096
- Email: vgovind@med.miami.edu
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
Contact:
- Emmely Pavila, B.A., B.S.
- Phone Number: 352-273-9562
- Email: empavila17@ufl.edu
-
Principal Investigator:
- Yan Wang, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Frequent alcohol use in the past 30 days based on responses on the Timeline Followback (TLFB; Sobell and Sobell, 2003)
- HIV positive
- Fluency in English
- Willingness to attempt alcohol abstinence for at least 30 days and then to attempt alcohol use on fewer days than at baseline after that
- Willingness to use smartphone applications and biosensor devices (i.e., breathalyzer device and wrist sensor) for alcohol use reduction purposes in the study. If participants do not have a compatible smartphone to use, they will be loaned one by the study
Exclusion Criteria:
- Psychiatric conditions that would interfere with participation in the study
- Current alcohol withdrawal as indicated by a score of 8 or higher on the Clinical Institute Withdrawal Scale (CIWA; Sullivan et al., 1989) or lifetime history of medically assisted detoxification
- Two positive breath alcohol concentration (BrAC) readings (i.e., > 0.00%) at an in-person screening appointment. After participants blow their first positive BrAC, they will be allowed to reschedule and participate at another time, however if they blow a second positive BrAC, they will be excluded from this study and offered referrals for alcohol treatment.
- Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- Psychosis or other severe psychiatric disability
- Pregnancy, nursing or lack of reliable birth control use for women who have not yet reached menopause
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Non-Contingent Condition
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
|
|
Experimental: mHealth and CM
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings.
Participants will also interact with a mobile health application to facilitate drinking reduction.
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
Participants will engage with an application designed to gamify drinking reduction.
|
|
Experimental: CM
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via smartphone breathalyzer readings
Time Frame: Baseline to 30 Days
|
Within-subject comparison between percent abstinent days based on smartphone breathalyzer readings during the 30-Day Phase 1 Contingency Management induction compared to the 30-day baseline period based on self-report on the timeline followback
|
Baseline to 30 Days
|
|
Predict percent days abstinent via smartphone breathalyzer readings based on risk factors.
Time Frame: Baseline to 30 Days
|
All participants will attempt to reduce alcohol consumption.
Only those who are able to will continue to the second phase of the intervention.
We will seek to identify which factors are predictive of abstinence.
|
Baseline to 30 Days
|
|
Perceived value and ease of use of novel contingency management strategies to reduce alcohol consumption.
Time Frame: 30 Days to 60 Days
|
Participants will engage in a Contingency Management program aimed at reducing alcohol consumption.
A novel CM delivery system will be used intended to gamify the process.
|
30 Days to 60 Days
|
|
Drinking reduction through Contingency Management will predict non-drinking outcomes
Time Frame: Baseline to 90 days
|
Participants who are able to successfully reduce their alcohol consumption may see other health benefits including reduced HIV viral load.
|
Baseline to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via wrist biosensor readings
Time Frame: Baseline to 60 Days
|
Among responders during the Phase 1 Contingency Management induction period, comparison among Phase 2 study conditions regarding percent abstinent days based on wrist biosensor readings.
Percent days abstinent at baseline based on self-report and based on smartphone breathalyzer readings during Phase 1 will be included in this model.
|
Baseline to 60 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via self-report
Time Frame: Baseline to 180 Days
|
Among responders during the Phase 1 Contingency Management induction period, comparison among Phase 2 study conditions regarding percent abstinent days during the post-intervention, follow-up period based on self-report assessed with the timeline followback from days 61-180.
Percent days abstinent at baseline based on self-report and based on smartphone breathalyzer readings during Phase 1 and based on wrist biosensor readings during Phase 2 will be included in this model.
|
Baseline to 180 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Leeman, Ph.D, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 10, 2022
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
September 1, 2026
Study Registration Dates
First Submitted
December 2, 2021
First Submitted That Met QC Criteria
December 9, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
July 31, 2025
Last Update Submitted That Met QC Criteria
July 29, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CED000000577 (Other Identifier: UF IRB Number)
- P01AA029543 (U.S. NIH Grant/Contract)
- PRO00035889 (Other Identifier: UFIRST)
- OCR41499 (Other Identifier: UF OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.